

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26

Rag1^{D600A}, a novel catalytically inactive RAG mouse model

Jason B Wong¹ and Jane A Skok^{1,*}

¹ Department of Pathology, New York University Langone School of Medicine, New York University, New York, New York, USA.

Keywords: *Rag1*; RAG; *Rag1*^{D600A}; *Rag1*^{D708A}; V(D)J recombination; B cell development; T cell development; antigen receptor diversity

* To whom correspondence should be addressed:

Email: jane.skok@nyumc.org

27 **Abstract**

28 The RAG complex (RAG1 and RAG2) can bind to recombination signal sequences of antigen
29 receptor loci gene segments and coordinate V(D)J recombination which is the primary method
30 of generating antigen receptor diversity. Previous biochemistry studies discovered RAG1 D600,
31 D708 and E962 residues as essential for catalytic DNA nicking and hairpin forming activity of
32 the RAG complex. Neutralization of each of the acidic residues does not impair DNA binding to
33 recombination signal sequence containing DNA substrates, but cleavage of the substrates is
34 severely compromised. These three acidic residues are thought to comprise a DDE motif that is
35 responsible for binding to a divalent cation that is necessary for cleavage activity. Although a
36 *Rag1^{-/-}*; RAG1-D708A transgenic mouse model system has been used to study dynamics of
37 RAG activity, transgenic expression may not precisely mimic expression from the endogenous
38 locus. In order to improve upon this model, we created *Rag1^{D600A}* mice that lack B and T cells
39 and demonstrate a developmental block at the pro-B and DN stages, respectively. Thus,
40 *Rag1^{D600A}* mice provide a novel mouse model system for studying the poorly understood
41 noncanonical functions of RAG1.

42

43 **Introduction**

44 Two RAG1-RAG2 monomers form a homodimer collectively called the RAG complex.
45 RAG can bind RSS sequences that flank V(D)J gene segments and coordinate a double
46 stranded (ds) DNA break at the junctions between recombining B cell receptor (BCR) or T cell
47 receptor (TCR) gene segments. Although RAG1 contains a catalytic site that executes nicking
48 and hairpin formation, RAG2 is an essential cofactor and depletion of the latter is sufficient to
49 cause severe immunodeficiency [1,2]. Both RAG1 and RAG2 are necessary and sufficient to
50 complete DNA cleavage in vitro [3,4].

51 In order to better understand the functional components of RAG1 and RAG2, various
52 truncations have been examined for DNA binding and cleavage activity. These studies identified
53 a minimal core region that contains DNA binding and cleavage activity [5–7]. For RAG1, the
54 core region contains a nonamer-binding domain, a dimerization and DNA binding domain
55 (DDBD), a pre-RNase H domain, an RNase-H like/insertion domain and a C-terminal domain.
56 The RAG2 core region comprises an N-terminal WD40 domain that folds into a β -propeller [8].

57 To further dissect the mechanisms of how RAG catalyzes DNA cleavage, highly
58 conserved amino acids were individually analyzed in RAG1. Three important acidic residues,
59 D600, D708 and E962 were identified. When each of these were individually mutated to a
60 nonpolar alanine (A), DNA cleavage activity was severely compromised although RAG retained
61 its ability to bind to the RSS of a DNA substrate [9–11]. This highlights a crucial role for these
62 three residues in RAG cleavage activity.

63 DNA sequence analysis of the 600 amino acid catalytic core of RAG1 provided evidence
64 that RAG1 evolved from DNA transposases of the Transib superfamily. Included in the
65 sequence conservation between RAG1 and the Transib superfamily transposases is a DDE
66 motif [12]. DDE family transposases and retroviral integrases use the DDE motif to coordinate
67 metal cations to execute DNA nicking as a first step of catalysis [13,14]. Since D600A, D708A
68 and E962 of RAG1 share sequence similarities to DDE motif transposases, it is tempting to
69 speculate that RAG-mediated cleavage functions in a similar method to DDE family
70 transposases. However, the three RAG1 amino acids are far away from each other on the linear
71 scale.

72 The early crystal structures of the RAG complex revealed that it takes on a “Y” shape,
73 where each of the two RAG1 proteins bind to each other at the base via the DDBD and RAG2
74 sits on top of the arms that extend up from the base [15]. Advances in structural analysis of
75 RAG revealed that the three RAG1 acidic residues (D600, D708, E962) are located in close 3D
76 proximity to one another [16,17]. The colocalization of the three essential acidic residues (D600,

77 D708, E962) at the active site of RAG1 provides further support that this is a DDE motif. RAG
78 has a strikingly similar structure to two other DDE family transposases: the well-known bacterial
79 transposase, Tn5 and the hAT family transposase, Hermes [16,18].

80 The combination of early RAG1 mutational, DNA sequence and protein structural
81 analyses strongly support the idea that D600, D708 and E962 of RAG1 comprise a DDE motif
82 that is essential for executing RAG mediated DNA cleavage in a similar manner to DDE family
83 transposases. RAG-mediated DNA breaks occur in two steps, nicking on one DNA strand at the
84 junction of the RSS and gene segment, followed by hairpin formation. A H₂O molecule is used
85 for a hydrolysis reaction to produce a nick. This leaves a 3' hydroxyl group on the first strand of
86 DNA that can attack the phosphodiester bond on the opposite strand in a direct
87 transesterification reaction [3]. D600, D708, and E962 are the three acidic residues that are
88 essential for stabilizing and coordinating divalent cations, such as Mg²⁺, to direct both of these
89 chemical reactions to initiate DNA breaks [3,8].

90 Neutralization of D600, D708 or E962 by mutating the aspartic acid or glutamic acid to a
91 nonpolar alanine (A) has been shown to be sufficient to disrupt DNA cleavage activity *in vitro*,
92 [9–11]. In order to conduct mouse experiments with catalytically inactive RAG, transgenic mice
93 were generated that express RAG1-D708A. These early transgenic mice used BAC integrations
94 to deliver transgenes that would have similar expression patterns to their endogenous
95 counterpart loci. The *Rag1*^{-/-}; RAG1-D708A transgenic mouse system enables the collection of
96 B and T cells in a context where RAG can bind to DNA, but cannot cleave. This has been an
97 important tool in many studies to investigate various properties of RAG [19–21].

98 Previous studies with mice harboring the HG RAG1-D708A BAC demonstrated
99 expression patterns that coincide with lymphocyte populations undergoing V(D)J recombination
100 in both B and T cell lineages [22]. However, when a gene is expressed outside of its
101 endogenous location, it likely does not precisely mimic the native gene in terms of expression
102 levels. In the case of the RAG1-D708A transgenic mice this has never been thoroughly

103 investigated. In order to prevent the endogenous wild-type allele from expressing wild-type
104 RAG1, it is necessary to cross the RAG1-D708A transgenic mouse onto a *Rag1*^{-/-} background.
105 Many studies use RAG1-D708A in combination with other pre-rearranged *Igh* or *Tcrb* transgenic
106 mice, which can lead to technical complications with breeding, delays in setting up new colonies
107 and lower efficiencies in generating mice with the desired genotype.

108 To circumvent these issues, we used CRISPR-Cas9 technology to make a point
109 mutation in the endogenous *Rag1* locus to generate a RAG1-D600A catalytically inactive
110 protein. *Rag1*^{D600A} mice fail to make mature B and T cells and have developmental blocks at
111 pro-B and DN2/3 cell stages respectively. Thus, we provide a novel mouse model in which
112 endogenous gene expression patterns are recapitulated for a catalytically inactive form of RAG
113 that can bind to, but cannot cleave DNA.

114

115 **Results**

116 We used CRISPR-Cas9 to genetically engineer mutations at the endogenous *Rag1*
117 locus to encode a RAG1-D600A protein. Briefly, mouse zygotes were injected with a mix
118 containing: sgRNAs, Cas9 mRNAs, and a single stranded donor oligonucleotide (ssODN).
119 Zygotes were cultured to the blastocyst stage and then transplanted into host mice. After pups
120 were born, tail tissue was collected and founder mice were assessed by PCR. The ssODN
121 repair template was designed to incorporate five different point mutations around the site
122 encoding the D600 residue of RAG1. To prevent the sgRNA from cutting the DNA after repair,
123 two silent mutations upstream of the D600 site were introduced to disrupt the PAM-sequence
124 and sgRNA binding capability. The GAT nucleotides that encode the aspartic acid (D) at residue
125 600 were converted to GCC to encode an alanine (A). In order to be able to easily detect alleles
126 with the point mutation, one additional silent mutation was designed three DNA base pairs
127 further downstream to create a *NaeI*/*NgoMIV* restriction site. Founder mice were identified by

128 PCR and sequenced to confirm that all the mutations from the ssODN were incorporated (**Fig**
129 **1A**). To detect *Rag1*^{D600A} alleles by PCR, primers were designed to create two different sizes
130 following restriction enzyme digest of the PCR product. Failure to digest the PCR product,
131 partial digestion or complete digestion were respectively indicative of wild-type, *Rag1*^{D600A/+}, or
132 *Rag1*^{D600A/D600A} mice (**Fig 1B**).

133

134 **Fig 1. Genetic engineering for generation of *Rag1*^{D600A} mice.** (A) DNA sequencing of the
135 *Rag1*^{D600A} allele is shown with amino acid translation directly underneath the DNA sequence.
136 DNA base differences highlighted in red, show mutations that disrupt secondary cutting or
137 introduce a NgoMIV restriction site that is underlined in black. (B) genotyping PCR schematic
138 and representative DNA gel for genotyping mice. Arrows represent PCR primers and the star
139 shows the location of the restriction enzyme cut site. The first lane is a 100bp DNA ladder. The
140 genotypes of mice are indicated above in subsequent lanes.

141

142 Since V(D)J recombination is essential for driving B and T cell development, it is
143 expected that *Rag1*^{D600A} mice will have a deficiency in B and T cells. To assess this, thymi
144 and spleens that harbor developing T cells and mature B cells respectively were dissected from
145 wild-type and *Rag1*^{D600A} mice. The *Rag1*^{D600A} thymi and spleen were decreased in size
146 compared to wild-type littermate controls, implying a severe immune cell deficiency (**Fig 2**).

147

148 **Fig 2. *Rag1*^{D600A} mice have smaller lymphoid organs compared to wild-type.**

149 Representative images of thymi (top) and spleens (bottom) dissected from wild-type (left) or
150 *Rag1*^{D600A} (right) mice.

151

152 To better interrogate B cell deficiency in *Rag1*^{D600A} mice, we performed flow cytometry
153 analysis of developing B cells from the bone marrow. As shown in **Fig 3**, *Rag1*^{D600A} mice failed

154 to generate mature and immature B cells. Additionally, there was a block at the pro-B cell stage
155 resulting from a failure in *Igh* recombination.

156

157 **Fig 3. *Rag*^{D600A} mice have a developmental block at the pro-B cell stage.** Representative
158 flow cytometry plots of bone marrow cells from wild-type (top) and *Rag*^{D600A} mice (bottom). Left
159 side is gated on CD19⁺, B220/CD45R⁺, IgM⁻ cells. Right side is gated on total bone marrow
160 cells.

161

162 To determine if B cell development is also blocked at the pre-B cell stage due to a failure
163 in *Igk* rearrangement, we crossed *Rag1*^{D600A} mice with mice containing a pre-rearranged heavy-
164 chain transgene (B1.8). *Rag1*^{D600A}; B1.8 mice also failed to make mature and immature B cells,
165 exhibiting a developmental block at the pre-B cell stage (**Fig 4**). Thus, the B1.8 allele allows B
166 cell development to proceed to the pre-B cell stage, but development cannot proceed past the
167 pre-B cell stage because RAG cannot recombine *Igk/Igl*.

168

169 **Fig 4. *Rag*^{D600A}; B1.8 mice have a developmental block at the pre-B cell stage.**

170 Representative flow cytometry plots of bone marrow cells from B1.8 (top) and *Rag*^{D600A}; B1.8
171 mice (bottom). Left side is gated on CD19⁺, B220/CD45R⁺, IgM⁻ bone marrow cells. Right side is
172 gated on total bone marrow cells.

173

174 RAG is important for V(D)J recombination in both B and T cells. As expected, T cell
175 development also appeared to be diminished based on the size of the thymus of *Rag1*^{D600A} mice
176 (**Fig 1**). To examine this further, we analyzed T cell development from the thymus by flow
177 cytometry. *Rag1*^{D600A} T cells had a strong developmental block at the DN stage of T cell
178 development. Additionally, these DN cells were almost exclusively (>95%) at the DN2/3 stage of
179 development (**Fig 5**). Together our results demonstrate that *Rag1*^{D600A} mice have developmental

180 blocks in B and T cell development. Our *in vivo* findings are consistent with the previously
181 published *in vitro* studies demonstrating that RAG1-D600A fails to catalyze DNA breaks during
182 V(D)J recombination. Thus, *Rag1*^{D600A} mice can be used as an improved mouse model for
183 future studies.

184

185 **Fig 5. *Rag*^{D600A} mice have a developmental block at the DN2/3 T cell stage.** Representative
186 flow cytometry plots of bone marrow cells from wild-type (top) and *Rag*^{D600A} mice (Bottom). Left
187 side is gated on Thy1.2⁺, TCRβ⁻ cells from the thymus. Right side is gated on the DN T cell gate.

188

189 Discussion

190 Three acidic residues on RAG1 that are essential for DNA cleavage activity [9–11],
191 D600, D708 and E962 are thought to form a DDE motif that can bind to divalent cations like
192 Ca²⁺, Mg²⁺ or Mn²⁺ to help coordinate the chemical reactions for nicking and hairpin formation.
193 Even though RAG1-D708A transgenic mice have been used extensively for analysis of RAG
194 binding to DNA in the absence of cleavage, some technical issues might persist. RAG1-D708A
195 transgenic mice express RAG1-D708A from a transgene instead of the native locus, which may
196 not precisely mimic the expression from its endogenous location. Additionally, use of these mice
197 require backcrossing into a *Rag1*^{-/-} background to prevent *Rag1* expression from the
198 endogenous locus. Here, we used CRISPR-cas9 to genetically engineer the endogenous *Rag1*
199 locus to produce *Rag1*^{D600A} mice.

200 Although we attempted to make both *Rag1*^{D600A} and *Rag1*^{D708A} mice, we failed to recover
201 any founder mice that harbored the *Rag1*^{D708A} allele. It is unclear why this is the case, but it is
202 possible that the sgRNA designed for the D708 site had off target binding activity that
203 decreased the efficiency of editing at the site of interest. Since we obtained founders for
204 *Rag1*^{D600A}, we did not continue further with the D708A design.

205 Early biochemistry experiments also tested cleavage activity by expressing D600C,
206 D708C, and E962C forms of RAG1 [9–11]. Cysteine changes the divalent ion binding
207 preference to Mn^{2+} instead of Mg^{2+} or Ca^{2+} . Interestingly, all three groups who performed these
208 experiments observed that RAG1-D708C, in the presence of Mn^{2+} , was uniquely able to rescue
209 *in vitro* cleavage activity. Since the D708C form of RAG1 was the only mutant able to rescue
210 cleavage activity it suggested that the D708 residue is especially important, which is perhaps
211 the reason why RAG1-D708A has been the favored form of the protein in previous studies.
212 However, our work here demonstrates that RAG1-D600 is essential for B and T cell
213 development. Thus, *Rag1*^{D600A} is a novel mouse model that implements improvements on the
214 *Rag1*^{-/-}; RAG1-D708A transgenic system. This mouse can be used for studies on the non-
215 canonical functions of RAG, which to-date have largely been ignored.

216

217 **Materials and Methods**

218 **Mice**

219 All mice were housed and cared for in accordance with IACUC guidelines and protocols
220 approved by NYUMC (protocol #: IA15-01468). B1.8 mice were used as previously described
221 [23].

222

223 **Generation of mutant mice using CRISPR-Cas9**

224 Mouse zygotes were injected with the following mix: *in vitro* transcribed 50ng/uL sgRNAs,
225 100ng/uL Cas9 mRNA (Trilink L-6125) and 50ng/uL ssODN (IDT custom oligos). Target
226 sequences were cloned into a Px461 plasmid using cut and paste cloning with a BbsI restriction
227 enzyme. T7 promoter sequences were added by PCR and the PCR product was used as
228 template to generate sgRNAs by *in vitro* transcription using the HiScribe T7 quick high yield

229 RNA synthesis kit (NEB E2050S) and purified by an RNeasy mini kit (Qiagen 74104). Primers
230 and oligos used are listed in S1 Table.

231

232 **Flow cytometry and antibodies**

233 Bone marrow and fetal liver cell populations were isolated from C57Bl/6 mice via cell sorting
234 and analyzed by flow cytometry. Antibodies for B and T cell analysis include: anti-CD45R/B220
235 (RA3-6B2), anti-CD19 (1D3), anti-IgM^p (AF6-78), anti-CD117/c-Kit (2B8), anti-CD25/IL2RA
236 (PC61), anti-CD90.2/Thy1.2 (53-2.1), anti-TCR β (H57-597), anti-CD8a (53-6.7), anti-CD4 (RM4-
237 5), anti-CD44 (IM7). These antibodies were obtained from either BD Pharmigen or eBioscience.
238 Cells were sorted using a FACS Aria I (BD). Data were also collected on an LSR II (BD) and
239 analyzed using FlowJo software.

240 **Acknowledgements**

241 JAS is supported by NIH grant, R35GM122515. JBW was previously supported by the T32
242 CA009161 training grant (Levy) and the 2T32 AI100853-06 (Reizis) training grant. *The funders*
243 *had no role in study design, data collection and analysis, decision to publish, or preparation of*
244 *the manuscript.*
245

246

247 **References**

- 248 1. Schwarz K, Gauss GH, Ludwig L, Pannicke U, Li Z, Lindner D, et al. RAG mutations in
249 human B cell-negative SCID. *Science*. 1996 Oct 4;274(5284):97–9.
- 250 2. Shinkai Y, Rathbun G, Lam KP, Oltz EM, Stewart V, Mendelsohn M, et al. RAG-2-
251 deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement.
252 *Cell*. 1992 Mar 6;68(5):855–67.
- 253 3. McBlane JF, van Gent DC, Ramsden DA, Romeo C, Cuomo CA, Gellert M, et al.


- 254 Cleavage at a V(D)J recombination signal requires only RAG1 and RAG2 proteins and
255 occurs in two steps. *Cell*. 1995;83(3):387–95.
- 256 4. Van Gent DC, Ramsden DA, Gellert M. The RAG1 and RAG2 proteins establish the
257 12/23 rule in V(D)J recombination. *Cell*. 1996;85(1):107–13.
- 258 5. Cuomo CA, Oettinger MA. Analysis of regions of RAG-2 important for V(D)J
259 recombination. *Nucleic Acids Res*. 1994;
- 260 6. Sadofsky MJ, Hesse JE, McBlane JF, Gellert M. Expression and V(D)J recombination
261 activity of mutated RAG-1 proteins. *Nucleic Acids Res*. 1994;22(3):550–550.
- 262 7. Sadofsky MJ, Hesse JE, Gellert M. Definition of a core region of RAG-2 that is functional
263 in V(D)J recombination. *Nucleic Acids Res*. 1994;22(10):1805–9.
- 264 8. Ru H, Zhang P, Wu H. Structural gymnastics of RAG-mediated DNA cleavage in V(D)J
265 recombination. *Curr Opin Struct Biol*. 2018;53(D):178–86.
- 266 9. Landree MA, Wibbenmeyer JA, Roth DB. Mutational analysis of RAG1 and RAG2
267 identifies three catalytic amino acids in RAG1 critical for both cleavage steps of V(D)J
268 recombination. *Genes Dev*. 1999 Dec 1;13(23):3059–69.
- 269 10. Kim DR, Dai Y, Mundy CL, Yang W, Oettinger M a. Mutations of acidic residues in RAG1
270 define the active site of the V(D)J recombinase. *Genes Dev*. 1999;13(23):3070–80.
- 271 11. Fugmann SD, Villey IJ, Ptaszek LM, Schatz DG. Identification of two catalytic residues in
272 RAG1 that define a single active site within the RAG1/RAG2 protein complex. *Mol Cell*.
273 2000 Jan;5(1):97–107.
- 274 12. Kapitonov V V., Jurka J. RAG1 Core and V(D)J Recombination Signal Sequences Were
275 Derived from Transib Transposons. Nemazee D, editor. *PLoS Biol*. 2005 May
276 24;3(6):e181.
- 277 13. Kennedy AK, Guhathakurta A, Kleckner N, Haniford DB. Tn10 Transposition via a DNA
278 Hairpin Intermediate. *Cell*. 1998 Oct;95(1):125–34.
- 279 14. Montañó SP, Rice PA. Moving DNA around: DNA transposition and retroviral integration.

- 280 Curr Opin Struct Biol. 2011 Jun;21(3):370–8.
- 281 15. Yin FF, Bailey S, Innis CA, Ciubotaru M, Kamtekar S, Steitz TA, et al. Structure of the
282 RAG1 nonamer binding domain with DNA reveals a dimer that mediates DNA synapsis.
283 Nat Struct Mol Biol. 2009;16(5):499–508.
- 284 16. Kim MS, Lapkouski M, Yang W, Gellert M. Crystal structure of the V(D)J recombinase
285 RAG1-RAG2. Nature. 2015;518(7540):507–11.
- 286 17. Ru H, Chambers MG, Fu TM, Tong AB, Liao M, Wu H. Molecular Mechanism of V(D)J
287 Recombination from Synaptic RAG1-RAG2 Complex Structures. Cell. 2015;163(5):1138–
288 52.
- 289 18. Kim MS, Chuenchor W, Chen X, Cui Y, Zhang X, Zhou ZH, et al. Cracking the DNA Code
290 for V(D)J Recombination. Mol Cell. 2018;70(2):358–370.e4.
- 291 19. Chaumeil J, Micsinai M, Ntziachristos P, Deriano L, Wang JMH, Ji Y, et al. Higher-Order
292 Looping and Nuclear Organization of Tcra Facilitate Targeted RAG Cleavage and
293 Regulated Rearrangement in Recombination Centers. Cell Rep. 2013;3(2):359–70.
- 294 20. Ji Y, Resch W, Corbett E, Yamane A, Casellas R, Schatz DG. The in vivo pattern of
295 binding of RAG1 and RAG2 to antigen receptor loci. Cell. 2010;141(3):419–31.
- 296 21. Chaumeil J, Micsinai M, Ntziachristos P, Roth DB, Aifantis I, Kluger Y, et al. The RAG2
297 C-terminus and ATM protect genome integrity by controlling antigen receptor gene
298 cleavage. Nat Commun. 2013;4:2231.
- 299 22. Yu W, Misulovin Z, Suh H, Hardy RR, Jankovic M, Yannoutsos N, et al. Coordinate
300 regulation of RAG1 and RAG2 by cell type-specific DNA elements 5' of RAG2. Science
301 (80-). 1999;285(5430):1080–4.
- 302 23. Sonoda E, Pewzner-jung Y, Schwers S, Taki S, Jung S, Eilat D, et al. B Cell
303 Development under the Condition of Allelic Inclusion. Immunity. 1997;6:225–33.
- 304

305 **Supporting Information**

306 **S1 Table. DNA oligos used for generation of *Rag1*^{D600A} mice.** Lower case letters for T7
307 primers are T7 promoter sequences. Lowercase letters for ssODNs represent mutations in
308 relationship to the germline sequences.
309


A

Rag1 WT

bioRxiv preprint doi: <https://doi.org/10.1101/698332>; this version posted July 10, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.

Rag1^{D600A}

B




wild-type


Rag1^{D600A}

Thymus


bioRxiv preprint doi: <https://doi.org/10.1101/698332>; this version posted July 10, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.

Spleen





bioRxiv preprint doi: <https://doi.org/10.1101/698332>; this version posted July 10, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.



bioRxiv preprint doi: <https://doi.org/10.1101/698332>; this version posted July 10, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.

